{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T05:15:54Z","timestamp":1769836554575,"version":"3.49.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T00:00:00Z","timestamp":1734480000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T00:00:00Z","timestamp":1734480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Forensic Toxicol"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s11419-024-00706-z","type":"journal-article","created":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T14:58:56Z","timestamp":1734533936000},"page":"179-189","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Urinary excretion profiles of the orexin receptor antagonist suvorexant and its metabolites"],"prefix":"10.1007","volume":"43","author":[{"given":"Misato","family":"Wada","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroe","family":"Kamata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriaki","family":"Shima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Nitta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidenao","family":"Kakehashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shihoko","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuntaro","family":"Matsuta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tooru","family":"Kamata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Munehiro","family":"Katagi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Nishioka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,12,18]]},"reference":[{"key":"706_CR1","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1254\/fpj.148.46","volume":"148","author":"Y Tanaka","year":"2016","unstructured":"Tanaka Y, Aoki I, Ishine T, Render JJ, Winrow CJ, Hisada S (2016) Preclinical and clinical results of dual orexin receptor antagonist, suvorexant (BELSOMRA\u00ae), a novel therapeutic agent for insomnia. Folia Pharmacol Jpn 148:46\u201356","journal-title":"Folia Pharmacol Jpn"},{"key":"706_CR2","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s40261-019-00764-x","volume":"39","author":"RE Wrishko","year":"2019","unstructured":"Wrishko RE, McCrea JB, Yee KL, Liu W, Panebianco D, Mangin E, Chakravarthy M, Martinez-Cantarin MP, Kraft WK (2019) Effect of CYP3A inhibition and induction on the pharmacokinetics of suvorexant: two phase I, open-label, fixed sequence trials in healthy subjects. Clin Drug Invest 39:441\u2013451","journal-title":"Clin Drug Invest"},{"key":"706_CR3","unstructured":"CDER (2014) Suvorexant NDA 204569, Clinical Pharmacology and Biopharmaceutics Review, Center for Drug Administration, Silver Spring, Maryland: www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2014\/204569Orig1s000ClinPharmR.pdf"},{"key":"706_CR4","unstructured":"U.S. Food and Drug Administration (FDA) (Press release), \"FDA approves new type of sleep drug, Belsomra\", [https:\/\/web.archive.org\/web\/20170214122028\/https:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm409950.htm]. Accessed 18 May 2024"},{"key":"706_CR5","unstructured":"Drugs.com., \"Belsomra Generic Belsomra Availability\", available from [https:\/\/www.drugs.com\/availability\/generic-belsomra.html], Accessed 18 May 2024"},{"key":"706_CR6","unstructured":"Pharmaceuticals and Medical Devices Agency, \"List of approved products in FY2014 (new drugs)\", available from [https:\/\/www.pmda.go.jp\/review-services\/drug-reviews\/review-information\/p-drugs\/0022.html], Accessed 18 May 2024"},{"key":"706_CR7","unstructured":"Australian Prescriber, \u201cSuvorexant for insomnia\u201d, available from [https:\/\/australianprescriber.tg.org.au\/articles\/suvorexant-for-insomnia.html], Accessed 18 May 2024"},{"key":"706_CR8","unstructured":"Hpr-rps.hres.ca. Government of Canada, \"Regulatory Decision Summary - Belsomra - Health Canada\", available from [https:\/\/dhpp.hpfb-dgpsa.ca\/review-documents\/resource\/RDS00475], Accessed 18 May 2024"},{"key":"706_CR9","first-page":"224","volume":"41","author":"S Sullinger","year":"2017","unstructured":"Sullinger S, Bryand K, Kerrigan S (2017) Identification of suvorexant in urine usingliquid chromatography-quadrupole\/time-of-flight mass spectrometry (LC-Q\/TOF-MS). J Anal Toxicol 41:224\u2013229","journal-title":"J Anal Toxicol"},{"key":"706_CR10","first-page":"759","volume":"54","author":"E Pegelow","year":"2016","unstructured":"Pegelow E, Borys D, Gummin D, Laubach E (2016) Clinical toxicity following suvorexant ingestion. Clin Toxicol 54:759\u2013760","journal-title":"Clin Toxicol"},{"key":"706_CR11","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1093\/jat\/bkx110","volume":"42","author":"B Waters","year":"2018","unstructured":"Waters B, Hara K, Ikematsu N, Takayama M, Matsusue A, Kashiwagi M, Kubo S (2018) Tissue distribution of suvorexant in three forensic autopsy cases. J Anal Toxicol 42:276\u2013283","journal-title":"J Anal Toxicol"},{"key":"706_CR12","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.jchromb.2016.10.042","volume":"1040","author":"M Carson","year":"2017","unstructured":"Carson M, Kerngan S (2017) Quantification of suvorexant in urine using gas chromatography\/mass spectrometry. J Chromatogr B 1040:289\u2013294","journal-title":"J Chromatogr B"},{"key":"706_CR13","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.jchromb.2015.07.056","volume":"1002","author":"SA Breidinger","year":"2015","unstructured":"Breidinger SA, Simpson RC, Mangin E, Woolf EJ (2015) Determination of suvorexant in human plasma using 96-well liquid-liquid extraction and HPLC with tandem mass spectrometric detection. J Chromatogr B 1002:254\u2013259","journal-title":"J Chromatogr B"},{"key":"706_CR14","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.jchromb.2018.05.006","volume":"1091","author":"B Skillman","year":"2018","unstructured":"Skillman B, Kemgan S (2018) Quantification of suvorexant in blood using liquid chromatography-quadrupole\/time of flight (LC-Q\/TOF) mass spectrometry. J Chromatogr B 1091:87\u201395","journal-title":"J Chromatogr B"},{"key":"706_CR15","first-page":"10577","volume":"23","author":"FP Busardo","year":"2019","unstructured":"Busardo FP, Vari MR, Di Trana A, Malaca S, Carlier J, Di Luca NM (2019) Drug-facilitated sexual assaults (DFSA): a serious underestimated issue. Eur Rev Med Pharmacol Sci 23:10577\u201310587","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"706_CR16","first-page":"1","volume":"2024","author":"K Skov","year":"2023","unstructured":"Skov K, Johansen SS, Linnet K, Nielsen MKK (2023) Automated enzymatic hydrolysis of urine samples for improved systematic toxicological analysis of drug-facilitated sexual assault cases. Drug Test Anal 2024:1\u201317","journal-title":"Drug Test Anal"},{"key":"706_CR17","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1093\/jat\/21.5.341","volume":"21","author":"SJ Salamone","year":"1997","unstructured":"Salamone SJ, Honasoge S, Brenner C, McNally AJ, Passarelli J, Goc-Szkutnicka K, Brenneisen R, elSohly MA, Feng S (1997) Flunitrazepam excretion patterns using the abuscreen OnTrak and OnLine immunoassays: comparison with GC-MS. J Anal Toxicol 21:341\u2013345","journal-title":"J Anal Toxicol"},{"key":"706_CR18","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1520\/JFS14827J","volume":"45","author":"A Negrusz","year":"2000","unstructured":"Negrusz A, Moore CM, Stockham TL, Poiser KR, Kern JL, Palaparthy R, Le NL, Janicak PG, Levy NA (2000) Elimination of 7-aminoflunitrazepam and flunitrazepam in urine after a single dose of Rohypnol\u00ae. J Forensic Sci 45:1031\u20131040","journal-title":"J Forensic Sci"},{"key":"706_CR19","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1093\/jat\/25.8.699","volume":"25","author":"H Snyder","year":"2001","unstructured":"Snyder H, Schwenzer KS, Pearlman R, McNally AJ, Tsilimidos M, Salamone SJ, Brenneisen R, ElSohly MA, Feng S (2001) Serum and urine concentrations of flunitrazepam and metabolites, after a single oral dose, by immunoassay and GC-MS. J Anal Toxicol 25:699\u2013704","journal-title":"J Anal Toxicol"},{"key":"706_CR20","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1093\/jat\/33.8.491","volume":"33","author":"M Forsman","year":"2009","unstructured":"Forsman M, Nystr\u00f6m I, Roman M, Berglund L, Ahlner J, Kronstrand R (2009) Urinary detection times and excretion patterns of flunitrazepam and its metabolites after a single oral dose. J Anal Toxicol 33:491\u2013501","journal-title":"J Anal Toxicol"},{"key":"706_CR21","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1093\/jat\/29.4.240","volume":"29","author":"K Tsujikawa","year":"2005","unstructured":"Tsujikawa K, Kuwayama K, Miyaguchi H, Kanamori T, Iwata Y, Inoue H, Kishi T (2005) Urinary excretion profiles of two major triazolam metabolites, alpha-hydroxytriazolam and 4-hydroxytriazolam. J Anal Toxicol 29:240\u2013243","journal-title":"J Anal Toxicol"},{"issue":"2","key":"706_CR22","doi-asserted-by":"publisher","first-page":"159","DOI":"10.3408\/jafst.801","volume":"26","author":"M Wada","year":"2021","unstructured":"Wada M, Shima N, Kamata T, Matsuta S, Ishikawa A, Nitta A, Asai R, Kakehashi H, Fujii S, Sasaki K, Kamata H, Katagi M (2021) Urinary excretion profiles of etizolam and its main metabolites after a single oral dose. Jpn J Forensic Sci Technol 26(2):159\u2013172","journal-title":"Jpn J Forensic Sci Technol"},{"issue":"10","key":"706_CR23","doi-asserted-by":"publisher","first-page":"882","DOI":"10.3109\/00498254.2015.1129565","volume":"46","author":"D Cui","year":"2016","unstructured":"Cui D, Cabalu T, Yee KL, Small J, Li X, Liu B, Maciolek C, Smith S, Liu W, McCrea JB, Prueksaritanont T (2016) In vitro and in vivo characterization of the metabolism and disposition of suvorexant in humans. Xenobiotica 46(10):882\u2013895","journal-title":"Xenobiotica"},{"key":"706_CR24","volume-title":"Substituted diazepam orexin receptor antagonists","author":"JM Bergman","year":"2008","unstructured":"Bergman JM, Breslin MJ, Coleman PJ, Cox CD, Mercer SP, Roecker AJ (2008) Substituted diazepam orexin receptor antagonists. Parent Application Publication, United States (US 2008\/0132490)"}],"container-title":["Forensic Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11419-024-00706-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11419-024-00706-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11419-024-00706-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T08:40:14Z","timestamp":1752136814000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11419-024-00706-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,18]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["706"],"URL":"https:\/\/doi.org\/10.1007\/s11419-024-00706-z","relation":{},"ISSN":["1860-8965","1860-8973"],"issn-type":[{"value":"1860-8965","type":"print"},{"value":"1860-8973","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,18]]},"assertion":[{"value":"8 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"There are no financial or other relations that could lead to a conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the ethics committee of Japanese Association of Forensic Science and Technology.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}